ature and mechanisms of cognitive deficits following chemotherapy: an (f)MRI study

Completed

• Conditions: cognitive deficits; memory and concentration problems; 10009841

• Registration Number: NL-OMON34510
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 180

Inclusion Criteria

All groups:
-female, independent of menopausal status
-age under 70 years (to allow use of the same neuropsychological test battery)
-sufficient proficiency in the Dutch language;Experimental group:
-newly diagnosed breast cancer patients without distant metastases who will receive anthracycline-based chemotherapy ;Breast cancer control group:
-newly diagnosed breast cancer patients without distant metastases who do not require chemotherapy;Healthy control group:
-healthy females, matched for age

Exclusion Criteria

All groups:
-previous malignancies
-excessive use of alcohol or drugs
-use of psychotropic medication
-neurologic or psychiatric disorders that may influence cognitive functioning
-conditions that preclude MRI examination.;Experimental group and breast cancer control group:
-relapse and/or metastases
- treatment with trastuzumab (Herceptin)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified